Anzeige
Mehr »
Login
Mittwoch, 02.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWUU | ISIN: US00534A1025 | Ticker-Symbol:
NASDAQ
01.04.25
21:59 Uhr
0,550 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INVIVYD INC Chart 1 Jahr
5-Tage-Chart
INVIVYD INC 5-Tage-Chart

Aktuelle News zur INVIVYD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.03.Invivyd adds venture capitalist Ajay Royan to board2
26.03.Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors2
20.03.Invivyd, Inc. Full Year Loss Decreases, But Misses Estimates3
20.03.Invivyd, Inc. - 10-K, Annual Report1
20.03.Invivyd GAAP EPS of -$1.43 misses by $0.04, revenue of $25.38M beats by $0.23M2
20.03.Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights597Achieved Q4 2024 PEMGARDA (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4...
► Artikel lesen
INVIVYD Aktie jetzt für 0€ handeln
20.03.Invivyd, Inc. - 8-K, Current Report1
05.03.Invivyd: Pemivibart behält Wirksamkeit gegen SARS-CoV-21
05.03.Invivyd reports pemivibart maintains efficacy against SARS-CoV-22
05.03.Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1165New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA (pemivibart) against LP.8.1 Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitute...
► Artikel lesen
05.03.Invivyd, Inc. - 8-K, Current Report-
24.02.Invivyd's (IVVD) Buy Rating Reiterated at HC Wainwright6
24.02.FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients3
24.02.Invivyd shares drop as FDA declines company's COVID-19 treatment EUA expansion2
24.02.FDA declines Invivyd's COVID-19 treatment EUA expansion10
24.02.Invivyd, Inc.: FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart)402FDA's reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent...
► Artikel lesen
24.02.Invivyd, Inc. - 8-K, Current Report-
18.02.Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far1
06.02.Invivyd tweaks COVID prophylactic playbook, teaming with NFL coach Harbaugh for awareness drive3
06.02.Pre-market Movers: Lipella Pharmaceuticals, Invivyd, Beasley Broadcast Group, Pasithea Therapeutics, Skyworks Solutions609OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.55 A.M. ET).In the Green Lipella Pharmaceuticals Inc. (LIPO) is up over 180%...
► Artikel lesen
Seite:  Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1